BRPI0919465A2 - dispositivo implantável para a liberação de risperidona e métodos de uso do mesmo - Google Patents

dispositivo implantável para a liberação de risperidona e métodos de uso do mesmo

Info

Publication number
BRPI0919465A2
BRPI0919465A2 BRPI0919465A BRPI0919465A BRPI0919465A2 BR PI0919465 A2 BRPI0919465 A2 BR PI0919465A2 BR PI0919465 A BRPI0919465 A BR PI0919465A BR PI0919465 A BRPI0919465 A BR PI0919465A BR PI0919465 A2 BRPI0919465 A2 BR PI0919465A2
Authority
BR
Brazil
Prior art keywords
risperidone
methods
implantable device
release
risperidone release
Prior art date
Application number
BRPI0919465A
Other languages
English (en)
Inventor
Harry Quandt
Petr Kuzma
Original Assignee
Endo Pharmaceuticals Solutions
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Pharmaceuticals Solutions filed Critical Endo Pharmaceuticals Solutions
Publication of BRPI0919465A2 publication Critical patent/BRPI0919465A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
BRPI0919465A 2008-09-30 2009-09-29 dispositivo implantável para a liberação de risperidona e métodos de uso do mesmo BRPI0919465A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10154808P 2008-09-30 2008-09-30
US11744808P 2008-11-24 2008-11-24
PCT/US2009/058810 WO2010039722A1 (en) 2008-09-30 2009-09-29 Implantable device for the delivery of risperidone and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0919465A2 true BRPI0919465A2 (pt) 2015-12-01

Family

ID=41557511

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919465A BRPI0919465A2 (pt) 2008-09-30 2009-09-29 dispositivo implantável para a liberação de risperidona e métodos de uso do mesmo

Country Status (12)

Country Link
US (2) US9078900B2 (pt)
EP (1) EP2344124B1 (pt)
JP (2) JP2012504146A (pt)
KR (1) KR101707791B1 (pt)
CN (1) CN102202646A (pt)
AU (1) AU2009298637B2 (pt)
BR (1) BRPI0919465A2 (pt)
CA (1) CA2739181C (pt)
IL (1) IL211952A (pt)
MX (1) MX2011003301A (pt)
RU (1) RU2510266C2 (pt)
WO (1) WO2010039722A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
US7858110B2 (en) 2003-08-11 2010-12-28 Endo Pharmaceuticals Solutions, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US9078900B2 (en) 2008-09-30 2015-07-14 Braeburn Pharmaceuticals Bvba Sprl Implantable device for the delivery of risperidone and methods of use thereof
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
WO2012019083A2 (en) * 2010-08-06 2012-02-09 Microchips, Inc. Biosensor membrane composition, biosensor, and methods for making same
CN104523565A (zh) * 2010-11-26 2015-04-22 约翰内斯堡威特沃特斯兰德大学 用于治疗精神分裂症的可植入头颅中的装置
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
TW201323011A (zh) * 2011-10-24 2013-06-16 Endo Pharmaceuticals Solutions 可植入雷沙吉蘭組合物及其治療方法
EP2770983B1 (en) * 2011-10-24 2017-04-19 Braeburn Pharmaceuticals, Inc. Implantable drug delivery compositions and methods of treatment thereof
ES2637387T3 (es) 2011-10-24 2017-10-13 Braeburn Pharmaceuticals, Inc. Composiciones de tizanidina implantables y procedimientos de tratamiento asociados
DE102013011399A1 (de) 2012-07-31 2014-02-06 Amw Gmbh Implantat mit Risperidon
SG11201507294WA (en) 2013-03-15 2015-10-29 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3285850A1 (en) 2015-04-23 2018-02-28 TARIS Biomedical LLC Drug delivery devices with drug-permeable component and methods
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
KR20210013089A (ko) 2018-05-24 2021-02-03 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
KR20210013088A (ko) 2018-05-24 2021-02-03 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
US11250125B2 (en) 2018-12-03 2022-02-15 Ebay Inc. Highly scalable permissioned block chains
FI4027973T3 (fi) * 2019-09-13 2026-01-14 Medincell S A Lääkkeensaattoformulaatioita
US11820890B2 (en) 2021-04-01 2023-11-21 Stratasys Inc Pulverulent thermoplastic polymer blends
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3948254A (en) 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3975350A (en) 1972-08-02 1976-08-17 Princeton Polymer Laboratories, Incorporated Hydrophilic or hydrogel carrier systems such as coatings, body implants and other articles
US4136145A (en) 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US4207890A (en) 1977-01-04 1980-06-17 Mcneilab, Inc. Drug-dispensing device and method
US4131604A (en) 1977-11-23 1978-12-26 Thermo Electron Corporation Polyurethane elastomer for heart assist devices
US4207809A (en) 1978-03-20 1980-06-17 Restaurant Technology, Inc. Dual reservoir coffee urn
US4386039A (en) 1980-02-11 1983-05-31 Thermo Electron Corporation Process for forming an optically clear polyurethane lens or cornea
US4523005A (en) 1981-10-30 1985-06-11 Thermedics, Inc. Extrudable polyurethane for prosthetic devices prepared from a diisocyanate, a polytetramethylene ether polyol, and 1,4-butane diol
US4469671A (en) 1983-02-22 1984-09-04 Eli Lilly And Company Contraceptive device
US4751133A (en) 1984-11-13 1988-06-14 Thermedics, Inc. Medical patches and processes for producing same
US4673565A (en) 1985-05-03 1987-06-16 E. I. Du Pont De Nemours And Company Pharmaceutical compositions containing hollow fine tubular drug delivery systems
US4720384A (en) 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
JPS62223112A (ja) 1986-03-25 1987-10-01 Rooto Seiyaku Kk 歯周病治療剤
US4743673A (en) 1986-12-19 1988-05-10 Tyndale Plains-Hunter, Ltd. Hydrophilic carboxy polyurethanes
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5207705A (en) 1988-12-08 1993-05-04 Brigham And Women's Hospital Prosthesis of foam polyurethane and collagen and uses thereof
US5254662A (en) 1990-09-12 1993-10-19 Polymedia Industries, Inc. Biostable polyurethane products
AU651654B2 (en) 1992-01-14 1994-07-28 Endo Pharmaceuticals Solutions Inc. Manufacture of water-swellable hydrophilic articles and drug delivery devices
US5266325A (en) 1990-09-28 1993-11-30 Hydro Med Science Division Of National Patent Development Corp. Preparation of homogeneous hydrogel copolymers
US5287295A (en) * 1991-05-30 1994-02-15 Motorola Method and apparatus for calibrating an electronic compass to account for alignment errors in the compass windings
WO1993022360A1 (en) 1992-04-24 1993-11-11 The Polymer Technology Group, Inc. Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range
US5629008A (en) 1992-06-02 1997-05-13 C.R. Bard, Inc. Method and device for long-term delivery of drugs
US5354835A (en) 1993-07-23 1994-10-11 Saudi Basic Industries Corporation Desalination process
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
DE69603577T2 (de) 1995-02-10 1999-11-25 Medtronic, Inc. Verfahren und vorrichtung zur verabreichung von analgetika
US5789411A (en) 1995-09-11 1998-08-04 Lance L. Gooberman P. C. Improvements to rapid opioid detoxification
PL189137B1 (pl) 1996-02-02 2005-06-30 Alza Corp Implantowane urządzenie do dostarczania substancji aktywnej
FR2752380B1 (fr) 1996-08-14 1998-10-30 Dow Corning Sa Procede de fabrication d'un dispositif a liberation controlee
AUPO251096A0 (en) 1996-09-23 1996-10-17 Cardiac Crc Nominees Pty Limited Polysiloxane-containing polyurethane elastomeric compositions
US7728049B2 (en) 1996-10-08 2010-06-01 Zamore Alan M Irradiation conversion of thermoplastic to thermoset polymers
US20010006677A1 (en) 1996-10-29 2001-07-05 Mcginity James W. Effervescence polymeric film drug delivery system
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
WO1999032095A1 (en) 1997-12-22 1999-07-01 Alza Corporation Rate controlling membranes for controlled drug delivery devices
JP4494629B2 (ja) 1997-12-30 2010-06-30 インターシア セラピューティクス,インコーポレイティド メンブレンプラグを備えた有益な作用剤の供給システム
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1237544A1 (en) 1999-12-16 2002-09-11 Trident Technologies, LLC System and method for extended delivery of a therapeutic agent with its receptor loading dose
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US20020028857A1 (en) 2000-03-31 2002-03-07 Holy Norman L. Compostable, degradable plastic compositions and articles thereof
CA2420854C (en) 2000-09-01 2013-07-30 Palmaya Pty Ltd Slow release pharmaceutical preparation and method of administering of same
US6887270B2 (en) 2002-02-08 2005-05-03 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
CN100586398C (zh) * 2002-05-23 2010-02-03 活性移植公司 植入体
JP4500679B2 (ja) * 2002-07-29 2010-07-14 アルザ・コーポレーシヨン パリペリドンを制御送達する方法および投薬形態物
US20090208540A1 (en) 2003-08-11 2009-08-20 Indevus Pharmaceuticals, Inc. Implantable device for the delivery of naltrexone and methods of use thereof
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
US7858110B2 (en) 2003-08-11 2010-12-28 Endo Pharmaceuticals Solutions, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
EP2633853A1 (en) * 2004-01-12 2013-09-04 The Trustees of The University of Pennsylvania Long-term delivery formulations and methods of use thereof
US20060110428A1 (en) 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
EP1781264B1 (en) 2004-08-04 2013-07-24 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
EP1888043A4 (en) 2005-03-11 2010-07-28 Endo Pharmaceuticals Solutions OCTREOTIDE FORMULATIONS WITH CONTROLLED RELEASE
MX362908B (es) * 2005-07-18 2019-02-21 Univ Pennsylvania Implantes que contienen fármacos y métodos de uso de los mismos.
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
CA2670454A1 (en) * 2006-11-22 2008-05-29 N.V. Organon Delivery system for a non-steroidal non-ionized hydrophilic drug
US20100210792A1 (en) * 2006-12-05 2010-08-19 David Taft Drug delivery
JP5536053B2 (ja) 2008-06-25 2014-07-02 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド. 離型剤を有するオクトレオチドインプラント
US9078900B2 (en) 2008-09-30 2015-07-14 Braeburn Pharmaceuticals Bvba Sprl Implantable device for the delivery of risperidone and methods of use thereof
JP2012504144A (ja) 2008-09-30 2012-02-16 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド. オクトレオチド送達用埋め込み可能型装置およびその使用方法

Also Published As

Publication number Publication date
JP2012504146A (ja) 2012-02-16
US20100080835A1 (en) 2010-04-01
CN102202646A (zh) 2011-09-28
MX2011003301A (es) 2011-06-09
AU2009298637B2 (en) 2015-08-13
JP5977324B2 (ja) 2016-08-24
EP2344124A1 (en) 2011-07-20
RU2510266C2 (ru) 2014-03-27
RU2011117331A (ru) 2012-11-10
AU2009298637A1 (en) 2010-04-08
US20160030337A1 (en) 2016-02-04
CA2739181A1 (en) 2010-04-08
JP2015083581A (ja) 2015-04-30
KR20120008018A (ko) 2012-01-25
EP2344124B1 (en) 2017-02-22
IL211952A0 (en) 2011-06-30
US9078900B2 (en) 2015-07-14
WO2010039722A1 (en) 2010-04-08
IL211952A (en) 2015-11-30
KR101707791B1 (ko) 2017-02-17
CA2739181C (en) 2017-03-14

Similar Documents

Publication Publication Date Title
BRPI0919465A2 (pt) dispositivo implantável para a liberação de risperidona e métodos de uso do mesmo
BRPI1013432A2 (pt) derivado de indolizina e uso do mesmo para propósitos médicos
BR112012010991A2 (pt) âncoras de implante e cabelo e sistemas e métodos para seu uso
BRPI0920752A2 (pt) dispositivo implantável para a distribuição de octreotídeo e métodos de uso do mesmo
BRPI0914034A2 (pt) dispositivo para limpeza de piso e método de limpeza de um piso
BRPI0909780A2 (pt) Composições e métodos para liberação de fármaco
BRPI0908379A2 (pt) sistemas e métodos para obter dentaduras customizadas
UY33132A (es) Proteínas solubles para su uso terapéutico
BRPI0916269A2 (pt) dispositivo de modificação de tecido e seu método de uso
BRPI1105769A2 (pt) insersores de dispositivo médico e processos de inserção e uso de dispositivos médicos.
BR112014012499A2 (pt) dispositivo de entrega e liberação para endoprótese
BRPI0917141A2 (pt) implante de stent dotado de área de assentamento estendida e método para uso do mesmo
BRPI0914004A2 (pt) agentes de aglutinação de receptor notch1 e métodos de uso mesmo
BR112013033466A2 (pt) uso de um sistema de liberação controlada e sistema de liberação controlada
BRPI0920348A2 (pt) aparelho para temporária anticoncepção masculina
BR112012013148A2 (pt) formulação farmacêutica e uso
BR112012001797A2 (pt) composto bicíclico e uso do mesmo para propósitos médicos
CO6821883A2 (es) Nuevos moduladores y métodos para su uso
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BR112012033650A2 (pt) dispositivo e método para irrigação-evacuação de cavidades corporais
BRPI0919794A2 (pt) dispositivo para uso intracorpóreo, e, composto
BR112013022861A2 (pt) dispositivo médico para uso com um estoma
BRPI0914862A2 (pt) método e dispositivo para colocação de implante
BRPI1010859A2 (pt) aptâmero para quimase, e uso do mesmo
BRPI0907150A2 (pt) Dispositivo e método para microelastografia

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2533 DE 23-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.